CONTROL BIONICS LIMITED — Investor Presentation 2023

May 29, 2023

==> picture [231 x 76] intentionally omitted <==

PRESENTED BY: Jeremy Steele DATE PRESENTED: 30 May 2023 VERSION: 1.0

Private & Confidential. Copyright © Control Bionics 2023

DISCLAIMER

==> picture [315 x 5] intentionally omitted <==

==> picture [720 x 405] intentionally omitted <==

----- Start of picture text -----

Our flagship product
----- End of picture text -----

EXECUTIVE SUMMARY

==> picture [229 x 114] intentionally omitted <==

4

LEADERSHIP TEAM

BOARD

==> picture [113 x 75] intentionally omitted <==

==> picture [77 x 77] intentionally omitted <==

Jeremy Steele

Roger Hawke

==> picture [104 x 69] intentionally omitted <==

Prof Rob Heard

Damian Lismore

==> picture [113 x 75] intentionally omitted <==

Peter Ford

==> picture [113 x 75] intentionally omitted <==

Brett Crowley

==> picture [54 x 54] intentionally omitted <==

Jeremy Steele

==> picture [48 x 48] intentionally omitted <==

Dominik Kucera

==> picture [52 x 52] intentionally omitted <==

Todd Tyler

==> picture [53 x 52] intentionally omitted <==

James Schorey

WHO IS CONTROL BIONICS?

==> picture [213 x 205] intentionally omitted <==

6

HOW WE WORK

	Opportunity origination	Product Selection	Trial/Rental	Purchase/funding	Payment terms
USA	- Our sales people have developed a network of referral sources to originate sales opportunities - These could be speech language pathologists (‘SLPs’), school districts, hospitals or the Veterans Administration (VA) - We have 9 sales people across the US as well as 3rd party distributors	- Our sales person works with the care team to select the preferred solution - Ensuring the Neuronode is part of that solution gives us a competitive advantage	- Most US funds require systems to be trialled for at least 30 days before approving funding - In many cases multiple systems need to be trialled before the one system can be recommended and approved	- We work with the local care team to submit a funding package on behalf of the client to the relevant insurer - Equipment is only shipped once written pre-approval given - We can only invoice once equipment is received by the client	- Varies by payor - Medicare typically pays 30-60 days post invoice - Private insurance typically pays in 90- 120 days (but can be up to 180 days)
Australia	- Our sales people have developed a network of referral sources to originate sales opportunities - These include SLPs, industry bodies and multi-site clinical practices - We have 5 sales people across Australia	- Our sales person works with the care team to select the preferred solution - An increasing number of referral partners will have their own Control Bionics system in- house to use for customer trials they lead themselves	- The NDIS allows for systems to be rented before an outright purchase, so in Australia ~40% of our systems shipped each month are for rentals (typically for 3 months) - The balance of our systems are an outright sale (often post a 30-day trial)	- The care team is responsible for submitting a funding application to the NDIS - Once approved, the system is shipped	- NDIS typically pays in 30 days

OUR PERFORMANCE IN FY23

forecast to grow more than 15% with revenue expected to top $5m

excess of 25% growth and the US over 10%

==> picture [191 x 197] intentionally omitted <==

8

OUR STRATERGY PRIORITIES FOR FY24

We expect organic revenue growth in excess of 20% for FY24, with both

==> picture [214 x 203] intentionally omitted <==

----- Start of picture text -----

NEW INITIATIVES
----- End of picture text -----

9

CORE PILLARS IN FY24

USA

We are forecasting growth in the US in excess of 15% for FY24 . This growth will be

==> picture [78 x 323] intentionally omitted <==

CORE PILLARS IN FY24

AUSTRALIA

We are forecasting strong organic growth in the Australian business in excess of 30% for FY24

==> picture [172 x 249] intentionally omitted <==

As the only Australian manufacturer of AAC equipment , we are positioned very strongly

CORE PILLARS IN FY24

JAPAN / INTERNATIONAL

==> picture [226 x 305] intentionally omitted <==

CORE PILLARS IN FY24

SOFTWARE

EMG device which will create a new revenue stream for the business* – using our

Our recent board appointee, Prof Rob Heard , is a highly credentialed Neurologist. He is

We have recently hired a new Product lead for our software, Dr Tom Allen . Tom is a PhD in

CORE PILLARS IN FY24

DROVE

==> picture [351 x 260] intentionally omitted <==

CORE PILLARS IN FY24

==> picture [511 x 291] intentionally omitted <==

3RD PARTY PRODUCTS

• We are advancing work on the balance of the 3[rd] party products we use in our Trilogy solution to improve margin, product attractiveness and scalability

• Our inhouse industrial designer and our investment in our software capabilities allows us to be more strategic in how we approach the business

CORE PILLARS IN FY24

OUR PEOPLE

==> picture [245 x 331] intentionally omitted <==

HOW GOOD IS THE OPPORTUNITY FOR CONTROL BIONICS?

There is a significant underserved market in this space with growth available to Control Bionics in its existing core markets of the US and Australia, our new market of Japan as well as untapped markets such as Europe We have identified a number of opportunities to extend the use of our core IP , the Neuronode, into new markets, which is not currently factored into our forecasts In addition, we think there are inorganic opportunities for us to participate in further industry consolidation

• We expect FY24 to be a significant year for Control Bionics

17

THANK YOU

JEREMY STEELE

jsteele@controlbionics.com +65 9011 3975

www.controlbionics.com